Since CD133+ GBM cells have originally been reported to have increased tumor initiating capability in vivo (3,8), a functional study was carried out to address the relevance of E2F2 to the tumorigenic properties of GBM, and its value as a therapeutic target for treatment of this highly aggressive brain tumor. This evidence concerns the gene E2F2 and glioblastoma.